Programme - Friday, October 8, 2021
All times are Central European Summer Time (CEST)
Live Talks will be available onDemand at the end of the respective Session
08.30 – 08.40 Welcome Address
Michael von Bergwelt, Munich, Germany
08.40 – 10.00 Session 1: Emerging Concepts / New Agents
Chair: Pedro Romero and Christoph Zielinski
08.40 – 09.00 01.01 - T cell exhaustion
Dietmar Zehn, Munich, Germany
09.00 – 09.20 01.02 - Targets to upregulate STING and endogenous retroviruses in tumors
Marcus Bosenberg, New Haven, CT, USA
09.20 – 09.40 01.03 - Resident memory T cells in anti-tumor immunity
Fathia Mami-Chouaib, Paris, France
09.40 – 10.00 01.04 - Clever-1
Maija Hollmen, Turku, Finland
10.00 – 10.30 Coffee Break
10.30 – 11.50 Session 2: Tumor microenvironment and microbiome in Immunotherapy
Chair: Eric Tartour and Maria Sibilia
10.30 – 10.50 02.01 - T helper subsets in cancer control and progression
Samuel Huber, Hamburg, Germany
10.50 – 11.10 02.02 - Role of Tumor-intrinsic PD-L1 Signaling in Adaptive Resistance to Immunotherapy
Brent Hanks, Durham, NC, USA
11.10 – 11.30 02.03 - The role of the microbiome in cancer therapy
Meriem Messaoudene, Montréal, Canada
11.30 – 11.50 02.04 - Role of tertiary lymphoid structures in cancer biology
Tullia Bruno, Pittsburgh PA, USA
11.50 – 12.50 Lunch Break
12.50 – 13.20 Satellite Symposium
Please click HERE for further information
13.20 – 14.40 Session 3: Vaccine Therapy
Chair: Paolo Ascierto and Barbara Seliger
13.20 – 13.40 03.01 - Unconventional Targets for Vaccine Therapies
Mads Hald Andersen, Copenhagen, Denmark
13.40 – 14.00 03.02 - Phase Ib trial with neoantigen-based vaccines in solid tumors
Patrick Ott, Boston, MA, USA
14.00 – 14.20 03.03 - Shared Immunogenic Cancer Antigens in Humans and Combination Immunotherapy Clinical Trials
that Exploit Those Antigens
Bernard A. Fox, Portland, OR, USA
14.20 – 14.40 03.04 - Therapeutic vaccines against HPV associated cancers
Toos Daemen, Groningen, The Netherlands
14.40 – 15.10 Coffee Break
15.10 – 15.50 Session 4: Pro & Contra Session
Chair: Ulrich Jäger and Marion Subklewe
15.10 – 15.30 04.01 - CAR T in AML – bridge to transplant vs standalone therapy
Saar Gill, Philadelphia, PA, USA
15.30 – 15.50 04.02 - Allogenic Stem Cell Transplantation in AML: Do we even need CAR T cells?
Nicolaus Kröger, Hamburg, Germany
15.50 – 15.55 Short Break
15.55 – 17.20 Session 5: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)
Chair: Samir Khleif and Sine Reker Hadrup
15.55 – 16.15 05.01 - Novel targets to enhance the efficacy of immune checkpoint blockades
X. Shirley Liu, Boston, MA, USA
16.15 – 16.35 05.02 - (De)classifying Human TILs to Promote immune Persistence and Predict Rational Therapeutics
Niroshana Anandasabapathy, New York, NY, USA
16.35 – 16.55 05.03 - In situ immunophenotyping of tumor infiltrating T-cells to predict response to immune checkpoint
inhibitors in kidney cancer
Sabina Signoretti, Boston, MA, USA
16.55 – 17.15 05.04 - Spatially resolved and high-dimensional characterisation of tumour immune microenvironment
remodelling following oncogene inhibition
Febe van Maldegem, London, United Kingdom
17.15 – 17.20 Short Break
17.20 – 17.50 Satellite Symposium
Please click HERE for further information
17.50 – 18.30 Session 6: “Lost in Translation”?
Chair: Mario Sznol and Jose Saro
17.50 – 18.10 06.01 - Anti-cancer vaccines
Cornelis Melief, Leiden, The Netherlands
18.10 – 18.30 06.02 - Next Generation Functional Drug Screening for Personalized Therapy
Philipp Staber, Vienna, Austria
​
​
ITOC8 has been granted 11 European CME credits